fashion -WSS

fashion

author：leisure time 2025-10-01 22:17:20 - browse：774

Here is STAT’s biotech scorecard, our regular ledger of stock-moving biotech events, for the third quarter:

Novo Nordiskis conducting a large clinical trial to prove that its GLP-1 drug Wegovy, in addition to helping people lose weight, also improves cardiovascular health. The SELECT study enrolled 17,500 participants who had overweight or obesity and had preexisting heart disease. The participants were then randomized to receive weekly injections of Wegovy or a matching placebo. The primary goal is to determine the extent to which Wegovy reduces the risk of heart attacks, strokes, and heart-related deaths. Wegovy is already a blockbuster drug based on weight loss alone, but proving an additional cardiovascular benefit could open the commercial floodgates.

BridgeBiowill report in July an analysis of all-cause mortality from a clinical trial of its heart drug acoramidis. The outcome is an important, second attempt at demonstrating benefit for acoramidis in a progressive heart disease called ATTR-CM. In December 2021, the drug performed no better than a placebo on a test of how far study participants could walk over the course of six minutes, failing to achieve its primary goal. But in this second part of the same study, BridgeBio will determine if acoramidis can significantly reduce hospitalizations and death over the course of 30 months.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Trump demands the U.S. pay no more for drugs than other countries … again
Next article： Elizabeth Holmes banned from government health programs

knowledge

WSS

McConnell is warmly embraced by Kentucky Republicans amid questions about his health

Judge in Trump's classified documents case questions use of out

My yearlong odyssey to get my son’s ADHD medication covered

'Brian's Song' at 50 still offers lessons about cancer for today

Readout Newsletter: BridgeBio, Madrigal, and Silicon Valley Bank

What to make of Gilead’s Trodelvy troubles and Elevation Oncology’s rise

focus

fashion

hotspot

After affirmative action ruling, medical educators look to 'holistic review'

Election results set back Medicaid expansion plans

Sports medicine is finally prioritizing gender equality

Trump used to be more articulate. What could explain the change?

Moonlake's readout produced a cash windfall. Risks remain

With heat waves through August, officials warn of health risks

BioMarin wins approval for gene therapy to treat hemophilia A

Sweden knocks USA out of World Cup in penalty kicks

BioMarin wins approval for gene therapy to treat hemophilia A

Trump used to be more articulate. What could explain the change?

knowledge

FDA clears AI tool for detecting skin cancer

A fugitive mob suspect in Greece is betrayed by his passion for hometown Naples soccer champions

Russia promises retaliation after Ukrainian drones hit a Russian tanker in 2nd sea attack in a day

Severe weather updates: 1 million customers without power in 11 states as storms pummel East Coast

With heat waves through August, officials warn of health risks

Humana cuts profit projections as Medicare Advantage costs soar

explore

focus

knowledge

focus